Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laromestrocel - Longeveron

Next Previous
Drug Profile

Laromestrocel - Longeveron

Alternative Names: Allogeneic Human Mesenchymal Stem Cells; LMSC; Lomecel-B; LOMECEL-B; Longeveron human mesenchymal stem cells; Mesenchymal stem cell therapy - Longeveron

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Longeveron
  • Developer Longeveron; National Heart, Lung and Blood Institute; University of Miami
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoplastic left heart syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Female sexual dysfunction

Highest Development Phases

  • Phase II Alzheimer's disease; Fatigue; Hypoplastic left heart syndrome
  • Phase I/II Dilated cardiomyopathy
  • No development reported Cognition disorders; Metabolic syndrome; Osteoarthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 18 Mar 2026 Longeveron plans a phase II pivotal registration trial in Dilated cardiomyopathy (In children) in USA in 2027
  • 17 Mar 2026 Laromestrocel - Longeveron is available for licensing as of 17 Mar 2026 for Alzheimer's disease http://www.longeveron.com
  • 25 Feb 2026 Pharmacodynamics and efficacy data from a phase-IIb trial in Fatigue released by Longeveron

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top